Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355945 | 0.84 | SAT1 (0.33) | — | |
| SCHEMBL17917288 | 0.84 | SAT1 (0.33) | — | |
| SCHEMBL12543777 | 0.83 | KDM1A (0.41) | KDM1AMAOAMAOBCHRM2CHRM1 | |
| SCHEMBL4569284 | 0.80 | KCNH3 (0.33) | KDM1AMAOAMAOBDAO | |
| SCHEMBL24170962 | 0.79 | NAMPT (0.34) | BRD4 | |
| SCHEMBL24171126 | 0.79 | NAMPT (0.34) | BRD4 | |
| SCHEMBL21099156 | 0.78 | CHRM2 (0.43) | KDM1AMAOAMAOBCHRM2CHRM1 | |
| SCHEMBL10153790 | 0.77 | SIGMAR1 (0.42) | KDM1AMAOAMAOBCHRM2CHRM1 | |
| SCHEMBL629231 | 0.77 | SIGMAR1 (0.47) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL21061372 | 0.77 | CHRM2 (0.42) | KDM1AMAOAMAOBCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | KDM1A 3350/4885MAOA 3486/4885MAOB 1591/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KDM1A 2400/4885MAOA 3912/4885MAOB 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.